Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 5/20 | 0.43 |
| ▸ | MMP2 | P08253 | 4/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 10/20 | 0.41 |
| ▸ | MMP13 | P45452 | 5/20 | 0.41 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL55550 | 0.90 | CTSK (0.50) | CTSKMMP9MMP2ADAM17MMP13 | |
| SCHEMBL56831 | 0.84 | MMP1 (0.51) | CTSKMMP9MMP2ADAM17MMP13 | |
| SCHEMBL8281067 | 0.83 | CTSK (0.54) | CTSKMMP9MMP2ADAM17POLB | |
| SCHEMBL27694744 | 0.78 | ADAM17 (0.53) | MMP9MMP2ADAM17MMP13MMP1 | |
| SCHEMBL27676230 | 0.78 | ADAM17 (0.53) | MMP9MMP2ADAM17MMP13MMP1 | |
| SCHEMBL48870 | 0.78 | ADAM17 (0.53) | MMP9MMP2ADAM17MMP13MMP1 | |
| SCHEMBL48288 | 0.78 | ADAM17 (0.53) | MMP9MMP2ADAM17MMP13MMP1 | |
| SCHEMBL4613139 | 0.73 | CTSK (0.76) | CTSK | |
| SCHEMBL4613133 | 0.73 | CTSK (0.76) | CTSK | |
| SCHEMBL4613136 | 0.73 | CTSK (0.76) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129406-B2 | Nonpeptide inhibitors of matrix metalloproteinases | SOUTHERN RESEARCH INSTITUTE (US) | 2012-03-06 | — | — | US | disclosed |
| EP-1735274-B1 | NONPEPTIDE INHIBITORS OF MATRIX METALLOPROTEINASES | SOUTHERN RES INST (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080312329-A1 | Nonpeptide Inhibitors of Matrix Metalloproteinases | SOUTHERN RESEARCH INSTITUTE (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312329-A1 | Nonpeptide Inhibitors of Matrix Metalloproteinases | SOUTHERN RESEARCH INSTITUTE (US) | 2008-12-18 | — | — | US | disclosed |
| WO-2005092844-A1 | NONPEPTIDE INHIBITORS OF MATRIX METALLOPROTEINASES | SOUTHERN RESEARCH INSTITUTE (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312329-A1 | Nonpeptide Inhibitors of Matrix Metalloproteinases | MMP1, MMP3, MMP10 | CTSK 338/4885MMP9 7/4885MMP2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.